Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study

BackgroundInhibitors of programmed cell death protein 1 (PD-1) and its ligand (PD-L1) (referred to hereafter as anti-PD-(L)1 agents) are approved to treat a variety of advanced-stage cancers. Incorporating these agents into neoadjuvant/adjuvant treatment regimens for early-stage cancers may provide...

Full description

Saved in:

Bibliographic Details
Main Authors:	Andrea Favre-Bulle, Maja Stanković, Tyler Mantaian, Claudia Frei, Sonja Schaefer, Sarah Sharon Gabriel, Demet Sönmez, Raquel Aguiar-Ibáñez
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-07-01
Series:	Frontiers in Immunology
Subjects:	immune checkpoint inhibitors melanoma nivolumab pembrolizumab renal cell carcinoma triple-negative breast cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1601377/full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Health impact of using anti-PD-(L)1 agents to treat early-stage cancers in Switzerland: a modeling study

Similar Items